Abla et al.
equiv) of NaBH4 and 420 mg (0.86 mmol, 1.45 equiv) of 4 were
used as starting materials. Purification by flash chromatography
(EtOAc/MeOH 8:2 v/v), by size-exclusion chromatography (MeOH),
and RP-HPLC (H2O/CH3CN 65:35 v/v) followed by lyophilization
led to 285 mg (0.32 mmol, 55%) of 10 as a white powder. Rf )
3.42-3.18 (m, 12H, H5, H4, H3, H2); 2.86-2.78 (m, 4H,
CH2SCH2); 2.58-2.45 (m, 2H, CH2Rf; 2.55 (t, J ) 6.96 Hz, 2H,
CH2CO); 2.26-2.06 (m, 2H, CH3CH2Rf); 1.16 (t, J ) 7.43 Hz,
3H, CH3CH2Rf). 13C NMR (CD3OD) δ 172.9, 103.5, 76.6, 76.6,
70.3, 73.3, 67.8, 61.3, 59.9, 36.4, 31.6, 27.07, 24.10, 22.04, 3.3.
19F NMR (CD3OD) δ -115.32 (2F), -117.53 (2F), -122.89 (4F),
-124.42 (2F), -124.70 (2F).
0.46 (EtOAc/MeOH/ H2O 7:2:1 v/v/v). Mp ) 169.4 °C. [R]25
)
D
-10.25° (c 1, MeOH). HRMS (ESI+) calcd for C27H38NO14SF13
([M + H]+): 880.1878, found 880.1878. 1H NMR (CD3OD) δ 4.35
(d, J ) 7.72 Hz, 1H, H1), 4.34 (d, J ) 7.73 Hz, 1H, H1), 4.21-4.13
(m, 2H, CH2OGlu), 3.96-3.84 (m, 6H, CH2OGlu, CH2OH, H6,),
3.72-3.65 (m, 2H, H6′), 3.38-3.19 (m, 8H, H5, H4, H3, H2),
2.85-2.79 (m, 4H, CH2SCH2), 2.60-2.44 (m, 2H, CH2Rf,), 2.57
(t, J ) 7.21 Hz, 2H, CH2CO). 13C NMR (CD3OD) δ 173.2, 103.4,
103.3, 76.6, 70.3, 73.3, 67.8, 67.7, 61.3, 61.0, 60.9, 36.23, 31.5,
27.1-22.0. 19F NMR (CD3OD) δ -82.4 (3F), -115.3 (2F), -122.9
(2F), -123.9 (2F), -124.3 (2F), -127.3 (2F).
N-1,1-Di[(2′,3′,4′,6′-tetra-O-acetyl-ꢀ-D-glucopyranosyl)oxymeth-
yl]acetoxyethyl-4-thia-tetradecanamide (14, H10-Diglu). The syn-
thetic procedure was essentially the same as for compound 9; 118
mg (0.68mmol, 1 equiv) of 1-decanethiol, 33.3 mg (0.88 mmol,
1.3 equiv) of NaBH4, and 440 mg (0.88 mmol, 1.3 equiv) of 4
were used as starting materials. Purification by size-exclusion
chromatography (MeOH) and RP-HPLC (H2O/CH3CN 60:40 v/v)
followed by lyophilization led to 232 mg (0.34mmol, 51%) of 14
as a white powder. Rf ) 0.45 (EtOAc/MeOH/ H2O 7:2:1 v/v/v).
Mp ) 129.9 °C, [R]25 ) -9.55° (c 1, MeOH), HRMS (ESI+)
N-Tris[(2′,3′,4′,6′-tetra-O-acetyl-ꢀ-D-glucopyranosyl)oxymethyl]-
methyl-4-thia-7,7,8,8,9,9,10,10,11,11,12,12,12-tridecafluorodode-
canamide (11, F6-Triglu). The synthetic procedure was essentially
the same as for compound 9; 150 mg (0.4 mmol, 1 equiv) of
1H,1H,2H,2H-perfluorooctylthioacetate, 19.7 mg (0.52 mmol, 1.3
equiv) of NaBH4, and 344 mg (0.52 mmol, 1.3 equiv) of 5 were
used as starting materials. Purification by size-exclusion chroma-
tography (MeOH) and RP-HPLC (H2O/CH3CN 65:35 v/v) followed
by lyophilization led to 217 mg (0.21mmol, 52%) of 11 as a white
powder. Rf ) 0.35 (EtOAc/MeOH/ H2O 7:2:1 v/v/v). Mp ) 180.2
D
calcd for C29H55NO14S ([M + H]+): 674.3416, found 674.3422.
1H NMR (CD3OD) δ 4.35 (d, J ) 7.72 Hz, 1H, H1,), 4.34 (d, J )
7.64 Hz, 1H, H1), 4.21-4.12 (m, 2H, CH2OGlu), 3.94-3.83 (m,
6H, CH2OGlu, CH2OH, H6), 3.72-3.66 (m, 2H, H6′), 3.39-3.19
(m, 8H, H5, H4, H3, H2,), 2.77 (t, J ) 7.29 Hz, 2H, CH2CO),
2.59-2.51 (m, 4H, CH2SCH2), 1.63-1.44 (m, 2H, SCH2CH2,), 1.32
(s, 14H, CH2), 0.93 (m, J ) 5.66 Hz, 3H, CH3). 13C NMR (CD3OD)
δ 173.6, 103.4, 103.3, 76.6, 70.2, 73.6, 67.8, 67.7, 61.3, 61.0, 60.9,
36.6, 31.6, 31.4, 29.3, 29.1, 29.0, 28.5, 27.2, 22.3, 13.1.
°C. [R]25 ) -19.75° (c 1, MeOH). HRMS (ESI+) calcd for
N-Tris[(2′,3′,4′,6′-tetra-O-acetyl-ꢀ-D-glucopyranosyl)oxymethyl]-
methyl-4-thia-tetradecanamide (15, H10-Triglu). The synthetic
procedure was essentially the same as for compound 9; 175 mg (1
mmol, 1 equiv) of 1-decanethiol, 56.9 mg (1.5 mmol, 1.5 equiv)
of NaBH4 and 995 mg (1.5 mmol, 1.5 equiv) of 5 were used as
starting materials. Purification by size-exclusion chromatography
(MeOH) and RP-HPLC (H2O/CH3CN 65:35 v/v) followed by
lyophilization led to 480 mg (0.57mmol, 57%) of 15 as a white
powder. Rf ) 0.20 (EtOAc/MeOH/ H2O 7:2:1 v/v/v). Mp ) 167
D
C33H48NO19SF13 ([M + H]+): 1042.2406, found 1042.2411. H
1
NMR (CD3OD) δ 4.14- 4.07 (m, 6H, H1, CH2OGlu), 3.74-3.64
(m, 6H, CH2Oglu, H6), 3.47-3.42 (m, 3H, H6′), 3.19-2.95 (m,
12H, H5, H4, H3, H2), 2.64-2.61 (m, 4H, CH2SCH2), 2.32 (t, J )
7.46 Hz, 2H, CH2CO), 2.35-2.29 (m, 2H, CH2Rf). 13C NMR
(CD3OD) δ 172.9, 103.5, 76.6, 70.2, 73.7, 67.8, 61.3, 59.9, 36.4,
31.5, 27.1, 22.0. 19F NMR (CD3OD) δ -82.4 (2F), -115.3 (2F),
-122.9 (2F), -123.9 (2F), -124.3 (2F), -127.3.
°C. [R]25 ) -19.55° (c 1, MeOH). HRMS (ESI+) calcd for
N-1,1-Di[(2′,3′,4′,6′-tetra-O-acetyl-ꢀ-D-glucopyranosyl)oxymeth-
yl]acetoxyethyl-4-thia-7,7,8,8,9,9,10,10,11,11,12,12-dodecafluoro-
tetradecanamide (12, H2F6-Diglu). The synthetic procedure was
essentially the same as for 9; 450 mg (1.04 mmol, 1 equiv) of 8,
53.8 mg (1.56 mmol, 1.5 equiv) of NaBH4, and 727 mg (1.45 mmol,
1.4 equiv) of 4 were used as starting materials. Purification by size-
exclusion chromatography (MeOH) and RP-HPLC (H2O/CH3CN
60:40 v/v) followed by lyophilization led to 399.9 mg (0.45 mmol,
44%) of 12 as a white powder. Rf ) 0.54 (EtOAc/MeOH/H2O 7:2:1
v/v/v). Mp ) 160 °C. [R]25D ) -3.95° (c 1, MeOH). HRMS (ESI+)
calcd for C29H43NO14SF12 ([M + H]+): 890.2285, found 890.2293.
1H NMR (CD3OD) δ 4.36 (d, J ) 7.71 Hz, 1H, H1), 4.34 (d, J )
7.77 Hz, 1H, H1), 4.20-4.13 (m, 2H, CH2OGlu), 3.94-3.84 (m,
6H, CH2OGlu, CH2OH, H6), 3.70-3.67 (m, 2H, H6′), 3.40-3.23
(m, 8H, H5, H4, H3, H2), 2.87-2.78 (m, 4H, CH2SCH2,), 2.61-2.45
(m, 2H, CH2Rf), 2.58 (t, J ) 7.08 Hz, 2H, CH2CO), 2.21-2.11
(m, 2H, CH3CH2Rf), 1.16 (t, J ) 7.41 Hz, 2H, CH3CH2). 13C NMR
(CD3OD) δ 173.3, 103.4, 103.3, 76.5, 70.1, 73.3, 67.9, 67.7, 61.2,
60.9, 36.2, 31.6, 27.1, 24.1, 22.0, 3.3. 19F NMR (CD3OD) δ -115.2
(2F), -117.5 (2F), -122.9 (4F), -124.4 (2F), -127.7 (2F).
N-Tris[(2′,3′,4′,6′-tetra-O-acetyl-ꢀ-D-glucopyranosyl)oxymethyl]-
methyl-4-thia-7,7,8,8,9,9,10,10,11,11,12,12-dodecafluorotetrade-
canamide (13, H2F6-Triglu). The synthetic procedure was essentially
the same as for 9; 200 mg (0.46 mmol, 1 equiv) of 8, 23.9 mg
(0.69 mmol, 1.5 equiv) of NaBH4, and 458 mg (0.69 mmol, 1.5
equiv) of 5 were used as starting materials. Purification by size-
exclusion chromatography (MeOH) and RP-HPLC (H2O/CH3CN
65:35 v/v) followed by lyophilization led to 291 mg (0.28 mmol,
60%) of 13 as a white powder. Rf ) 0.33 (EtOAc/MeOH/H2O 7:2:1
D
C35H65NO19S ([M + H]+): 836.3944, found 836.3947.1H NMR
(CD3OD) δ 4.22 (d, J ) 7.71 Hz, 3H, H1), 4.19 (d, J ) 10.11 Hz,
3H, CH2OGlu), 3.83 (d, J ) 10.26 Hz, 3H, CH2OGlu), 3.79-3.74
(m, 3H, H6), 3.59-3.57 (m, 3H, H6′), 3.26-3.06 (m, 12H, H5, H4,
H3, H2), 2.60 (t, J ) 7.27 Hz, 2H, CH2CO), 2.47-2.36 (m, 4H,
CH2SCH2,), 1.51-1.45 (m, 2H, SCH2CH2), 1.19 (s, 14H, CH2),
0.80 (t, J ) 6.32 Hz, 3H, CH3). 13C NMR (CD3OD) δ 173.0, 103.4,
76.6, 76.6, 70.2, 73.3, 67.9, 61.4, 59.9, 36.8, 31.4, 29.3, 29.1, 29.1,
28.6, 27.1, 22.4, 13.1.
N-1,1-Di[(2′,3′,4′,6′-tetra-O-acetyl-ꢀ-D-glucopyranosyl)oxymeth-
yl]acetoxyethyl-4-thia-hexadecanamide (16, H12-Diglu). The syn-
thetic procedure was the same as for 9; 150 mg (0.57 mmol, 1
equiv) of 1-dodecanethiol, 27.6 mg (0.80 mmol, 1.4 equiv) of
NaBH4, and 0.4 g (0.80 mmol, 1.4 equiv) of 4 were used as starting
materials. Purification by size exclusion chromatography (MeOH)
followed by lyophilization led to 0.21 g (0.29 mmol, 53%) of 16
as a white powder. Rf ) 0.43 (EtOAc/MeOH/H2O 7:2:1 v/v/v).
Mp ) 125.4 °C. [R]25D ) -1.65° (c,1,MeOH). HRMS (ESI+) calcd
for C31H59NO14S ([M + H]+): 702.3729, found 702.3727.1H NMR
(CD3OD) δ 4.34 (d, J ) 7.69 Hz, 1H, H1), 4.33 (d, J ) 7.71 Hz,
1H, H1), 4.21-4.13 (m, 2H, CH2OGlu), 3.96-3.83 (m, 6H,
CH2OGlu, CH2OH, H6), 3.72-3.65 (m, 2H, H6′), 3.39-3.19 (m,
8H, H5, H4, H3, H2), 2.71 (t, J ) 7.01 H, 2H, CH2CO), 2.59-2.51
(m, 4H, CH2SCH2), 1.63-1.55 (m, 2H, SCH2CH2), 1.32 (s, 18H,
CH2), 0.92 (t, J ) 6.25 Hz, 3H, CH3). 13C NMR (CD3OD) δ 173.6,
103.4, 103.3, 76.6, 70.2, 73.6, 67.8, 67.7, 61.3, 61.0, 60.9, 36.6,
31.4, 29.4, 29.3, 29.1, 29.0, 28.6, 27.1, 22.4, 13.1.
N-Tris[(2′,3′,4′,6′-tetra-O-acetyl-ꢀ-D-glucopyranosyl)oxymethyl]-
methyl-4-thia-hexadecanamide (17, H12-Triglu). The synthetic
procedure was essentially the same as for compound 9; 100 mg
(0.49 mmol, 1 equiv) of 1-dodecanethiol, 24.29 mg (0.64 mmol,
1.3 equiv) of NaBH4, and 424 mg (0.64 mmol, 11.3 equiv) of 5
were used as starting materials. Purification by size-exclusion
v/v/v). Mp ) 177.5 °C. [R]25 ) -18.25° (c 1, MeOH). HRMS
D
(ESI+) calcd for C35H53NO19SF12 ([M + H]+): 1052.2813, found
1052.2826. -115.2 (2F), -122.8 (2F), -123.8 (2F), -124.2 (2F),
-127.3. 1H NMR (CD3OD) δ 4.36-4.30 (m, 6H, H1, CH2OGlu);
3.97-3.87 (m, 6H, CH2OGlu, H6); 3.76-3.65 (H6’, m, 3H);
8152 J. Org. Chem. Vol. 73, No. 21, 2008